Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par's Xalatan Generic Delayed Until 2011 Under Patent Ruling

This article was originally published in The Pink Sheet Daily

Executive Summary

Two of three Pfizer patents for the glaucoma treatment are valid, a Trenton, N.J. federal court says. If the court's ruling is affirmed on appeal, Par would lose any 180-day generic marketing exclusivity that attaches to the two valid patents.

You may also be interested in...



Xalatan Patent Ruling

A D.C. federal appeals court upheld a patent ruling that bars Par from launching its generic of Pfizer's glaucoma agent Xalatan before 2011

Xalatan Patent Ruling

A D.C. federal appeals court upheld a patent ruling that bars Par from launching its generic of Pfizer's glaucoma agent Xalatan before 2011

Teva Accupril Generic Delayed Until 2007; Pfizer Patent Is Valid, Court Says

If upheld on appeal, the decision would eliminate Teva’s 180-day exclusivity period and make a challenge to Pfizer’s own generic moot. A New Jersey federal judge finds there was no inequitable conduct before the PTO regarding Pfizer’s patent for its ACE inhibitor.

Topics

UsernamePublicRestriction

Register

PS060234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel